City
Epaper

Initial findings on plasma therapy trial did not show promising evidence: AIIMS

By ANI | Updated: August 6, 2020 16:20 IST

The trial conducted by All India Institute of Medical Sciences (AIIMS) for convalescent plasma therapy on COVID-19 patients did not show much clinical benefit in reducing fatality risk caused due to the virus.

Open in App

The trial conducted by All India Institute of Medical Sciences (AIIMS) for convalescent plasma therapy on COVID-19 patients did not show much clinical benefit in reducing fatality risk caused due to the virus.

"These are initial analyses. There were two groups of 15 patients each on whom a randomised control trial was done to know the effectiveness of plasma therapy. One group received standard treatment protocol while the other group received convalescent plasma therapy along with standard treatment. It was noted that mortality was similar in both the groups with no much clinical benefits to the patients," Dr Randeep Guleria, Director at AIIMS told .

"It is also important to note that we need more evidence on it to conclude anything. Current evidence suggests that convalescent plasma is safe, does not cause any harm to a patient. But at the same time, it (plasma therapy) is not very effective and hence should be used prudently," Dr Guleria further said.

It may be noted that the Union Health Ministry in its clinical management protocol for COVID19 patients has described the use of convalescent plasma therapy as one of the investigational therapies.

The treatment protocol states that convalescent plasma therapy may be considered in patients with the moderate disease who are not improving (oxygen requirement is progressively increasing) despite the use of steroids.

The dose for convalescent plasma can be variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hours).

"There are special prerequisites while considering convalescent plasma. It includes ABO compatibility and cross-matching of the donor plasma. Recipients should be closely monitored for several hours post-transfusion for any transfusion related adverse events. However, the use of convalescent plasma should be avoided in patients with IgA deficiency or immunoglobulin allergy," read clinical guidelines.

Meanwhile, the Indian Council of Medical Research (ICMR) is also conducting trials to evaluate the efficacy of plasma therapy, however, results have not been published yet.

( With inputs from ANI )

Tags: All India Institute Of Medical SciencesAiims
Open in App

Related Stories

National“AIIMS Changes Picture Of Himachal Pradesh,” Says BJP President Rajeev Bindal (Watch Video)

NationalJagdeep Dhankhar Health Update: Vice President of India Discharged From AIIMS; Advised Complete Rest

NationalVice President Jagdeep Dhankhar Hospitalised at AIIMS After Complaining of Chest Pain and Uneasiness

HealthMental Health at Risk: AIIMS Psychiatrist Warns of Obesity-Linked Anxiety and Depression

NationalEx-Delhi AIIMS Doctor Alleges Ignorance on Delhi-Bound IndiGo Flight

National Realted Stories

NationalIndia's changemakers speak: Padma awardees reflect on recognition and responsibility

NationalBSF arrests 4 B'deshi smugglers along Indo-Bangla border; seizes contraband

NationalRS by-election: BJP's Satyanarayana to be NDA candidate from Andhra Pradesh

NationalGovt targets 100 GW of nuclear power capacity by 2047 to boost energy security

National'Insult to Hindu sentiments: Raj BJP chief slams Kharge